Novel Targeted Treatment for Triple Negative Breast Cancer
Receptor Targeted Delivery for Antineoplastic Agents to Breast Cancer Cells
Tags: The University of Sydney, Australia, Healthcare & Lifesciences
This innovative therapy combines an antineoplastic agent with an LHRH (Luteinising hormone release hormone) peptide targeting overexpressed receptors in triple negative breast cancer (TNBC), promising targeted treatment with minimal side effects. The drug acts like a 'Trojan Horse,' entering and destroying cancer cells without harming normal cells. It is designed as a sole therapy for TNBC and could potentially treat multiple cancer types that overexpress LHRH.
IP Type or Form Factor: Patent Pending; Platform
TRL: Not specified
Industry or Tech Area: Pharmaceutical Engineering; Healthcare Provider
